Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Lenalidomide and Paclitaxel in Prostate Cancer

This study has been terminated.
(Slow Accrual)
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: July 3, 2009
Last updated: December 10, 2015
Last verified: December 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)